
There is currently no warning information available for this product. We apologize for any inconvenience.
There is currently no manufacturer warning information available for this drug.
GRANIX is indicated to reduce the duration of severe neutropenia in patients with non‑myeloid malignancies receiving myelosuppressive anti‑cancer drugs associated with a clinically significant incidence of febrile neutropenia.
Tbo-filgrastim is a non-glycosylated recombinant methionyl human granulocyte colony-stimulating growth factor (r-metHuG-CSF) manufactured by recombinant DNA technology using the bacterium strain E coli K802. It has a molecular weight of approximately 18.8 kDa and is composed of 175 amino acids. The endogenous human G-CSF is glycosylated and does not have the additional methionine amino acid residue in its NH2 terminal end.
The product is a sterile, clear, colorless, preservative-free solution containing tbo-filgrastim, glacial acetic acid, sorbitol, polysorbate 80, sodium hydroxide, and Water for Injection. The product is available in single-use prefilled syringes that contain either 300 mcg or 480 mcg of tbo-filgrastim at a fill volume of 0.5 mL or 0.8 mL, respectively. See table below for product composition of each single-use prefilled syringe.
|
Product Composition |
||
|
300 mcg/0.5 mL Syringe |
480 mcg/0.8 mL Syringe |
|
|
Tbo-filgrastim |
300 mcg |
480 mcg |
|
Glacial Acetic Acid |
0.3 mg |
0.48 mg |
|
Polysorbate 80 |
0.0275 mg |
0.044 mg |
|
Sorbitol |
25 mg |
40 mg |
|
Sodium Hydroxide |
q.s. to pH 4.2 |
q.s. to pH 4.2 |
|
Water for Injection |
q.s. to 0.5 mL |
q.s. to 0.8 mL |